Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX)‘s stock had its “equal weight” rating restated by research analysts at Barclays PLC in a research report issued on Wednesday, May 10th. They currently have a $20.00 price target on the specialty pharmaceutical company’s stock. Barclays PLC’s target price suggests a potential upside of 47.93% from the company’s current price.
Other analysts also recently issued research reports about the stock. Deutsche Bank AG set a $20.00 price target on shares of Valeant Pharmaceuticals Intl and gave the company a “hold” rating in a research report on Saturday, January 21st. Wells Fargo & Co set a $11.00 price objective on shares of Valeant Pharmaceuticals Intl and gave the stock a “sell” rating in a report on Saturday, February 25th. Jefferies Group LLC set a $18.00 price objective on shares of Valeant Pharmaceuticals Intl and gave the stock a “buy” rating in a report on Saturday, May 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $19.00 price objective (up from $18.00) on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, May 10th. Finally, Piper Jaffray Companies reaffirmed an “outperform” rating and set a $10.00 price objective on shares of Valeant Pharmaceuticals Intl in a report on Friday, April 14th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $22.35.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded up 0.37% during mid-day trading on Wednesday, reaching $13.52. The company’s stock had a trading volume of 24,297,911 shares. Valeant Pharmaceuticals Intl has a 52-week low of $8.31 and a 52-week high of $32.74. The company’s market cap is $4.70 billion. The company has a 50-day moving average price of $10.55 and a 200 day moving average price of $13.75.
Valeant Pharmaceuticals Intl (NYSE:VRX) last posted its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $1.93. Valeant Pharmaceuticals Intl had a negative net margin of 22.17% and a positive return on equity of 43.81%. The business had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $2.17 billion. During the same quarter last year, the firm posted ($1.08) EPS. Valeant Pharmaceuticals Intl’s revenue was down 11.1% compared to the same quarter last year. Equities analysts expect that Valeant Pharmaceuticals Intl will post $3.89 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2017/05/20/valeant-pharmaceuticals-intls-vrx-equal-weight-rating-reiterated-at-barclays-plc-updated.html.
In related news, CFO Paul Herendeen purchased 24,000 shares of the firm’s stock in a transaction dated Tuesday, March 14th. The shares were purchased at an average cost of $10.72 per share, for a total transaction of $257,280.00. Following the completion of the transaction, the chief financial officer now directly owns 174,000 shares in the company, valued at approximately $1,865,280. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Schutter Richard U. De purchased 10,000 shares of the firm’s stock in a transaction dated Wednesday, March 15th. The shares were bought at an average price of $10.80 per share, for a total transaction of $108,000.00. Following the completion of the transaction, the director now owns 25,190 shares of the company’s stock, valued at $272,052. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 3,054,000 shares of company stock worth $33,103,280. Company insiders own 16.37% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Paulson & CO. Inc. acquired a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter valued at approximately $281,463,000. ValueAct Holdings L.P. raised its position in shares of Valeant Pharmaceuticals Intl by 20.0% in the first quarter. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company’s stock valued at $198,509,000 after buying an additional 3,002,963 shares during the last quarter. Norges Bank acquired a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter valued at approximately $39,286,000. Renaissance Technologies LLC raised its position in shares of Valeant Pharmaceuticals Intl by 573.6% in the fourth quarter. Renaissance Technologies LLC now owns 2,913,089 shares of the specialty pharmaceutical company’s stock valued at $42,294,000 after buying an additional 2,480,600 shares during the last quarter. Finally, Saba Capital Management L.P. raised its position in shares of Valeant Pharmaceuticals Intl by 132.4% in the first quarter. Saba Capital Management L.P. now owns 2,315,900 shares of the specialty pharmaceutical company’s stock valued at $25,544,000 after buying an additional 1,319,311 shares during the last quarter. 64.34% of the stock is owned by institutional investors.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.